Prognostic impact of chromosomal aberrations in Ewing tumours

[1]  O. Haas,et al.  Felix Mitelman: Database of chromosome aberrations in cancer , 2002, Human Genetics.

[2]  J. Squire,et al.  Acquisition of secondary structural chromosomal changes in pediatric ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome , 2001, Cancer.

[3]  M. Gessler,et al.  Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. , 2001, The American journal of pathology.

[4]  A. Sandberg,et al.  Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors. , 2000, Cancer genetics and cytogenetics.

[5]  P. Ambros,et al.  Molecular Cytogenetics in Ewing Tumors: Diagnostic and Prognostic Information , 2000, Oncology Research and Treatment.

[6]  A. Craft,et al.  Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Wei,et al.  Prognostic impact of INK4A deletion in Ewing sarcoma , 2000, Cancer.

[8]  M. Ladanyi,et al.  Prognostic impact of P53 status in Ewing sarcoma , 2000, Cancer.

[9]  C. Blomqvist,et al.  Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. , 2000, European journal of cancer.

[10]  S. Knuutila,et al.  Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. , 1999, Cancer genetics and cytogenetics.

[11]  P. Ambros,et al.  Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors , 1999, Genes, chromosomes & cancer.

[12]  W. Winkelmann,et al.  Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: The CESS 86 experience , 1999 .

[13]  F. Mertens,et al.  Cytogenetic aberrations in Ewing sarcoma: are secondary changes associated with clinical outcome? , 1999, Medical and pediatric oncology.

[14]  O. Myklebost,et al.  Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas. , 1998, British Journal of Cancer.

[15]  S. Knuutila,et al.  DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. , 1998, The American journal of pathology.

[16]  W. Gerald,et al.  EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Fletcher,et al.  Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. , 1998, Cancer genetics and cytogenetics.

[18]  H. Kovar,et al.  Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors , 1997, Oncogene.

[19]  S. Ferrari,et al.  Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Lion,et al.  Demonstration of the translocation der(16)t(1;16)(q12;q11.2) in interphase nuclei of ewing tumors , 1996, Genes, chromosomes & cancer.

[21]  A. Llombart‐Bosch,et al.  Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. , 1996, Seminars in diagnostic pathology.

[22]  O. Delattre,et al.  Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Mitelman.  ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .

[24]  N. Dracopoli,et al.  Current protocols in human genetics , 1994 .

[25]  H. Kovar,et al.  Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. , 1994, British Journal of Cancer.

[26]  T. Triche,et al.  The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.

[27]  H. Jürgens,et al.  Ewing's sarcoma and peripheral primitive neuroectodermal tumor. , 1994, Current opinion in oncology.

[28]  G. Thomas,et al.  Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes. , 1994, Cancer genetics and cytogenetics.

[29]  H. Jürgens,et al.  Treatment of soft tissue sarcoma in childhood and adolescence: A report of the german cooperative soft tissue sarcoma study , 1992, Cancer.

[30]  P. D. de Jong,et al.  Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints , 1992, Genes, chromosomes & cancer.

[31]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[32]  H Kovar,et al.  MIC2 is a specific marker for ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration , 1991, Cancer.

[33]  A. Aurias,et al.  Chromosomes in Ewing's sarcoma. II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16). , 1988, Cancer genetics and cytogenetics.

[34]  E. Korn,et al.  Effective sample sizes for confidence intervals for survival probabilities. , 1987, Statistics in medicine.

[35]  T. Triche,et al.  Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Israel,et al.  Chromosome translocation in peripheral neuroepithelioma. , 1984, The New England journal of medicine.

[37]  DavidM. O. Becroft,et al.  CHROMOSOME TRANSLOCATION IN EXTRASKELETAL EWING'S TUMOUR , 1984, The Lancet.

[38]  Meyerhoff Jo.  Exacerbation of psoriasis with meclofenamate. , 1983 .

[39]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[40]  I. Cohen,et al.  Additional chromosome 1q aberrations and der(16)t(1;16), correlation to the phenotypic expression and clinical behavior of the Ewing family of tumors , 2004, Journal of Neuro-Oncology.

[41]  C. Blomqvist,et al.  Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma , 2004, Cancer Chemotherapy and Pharmacology.

[42]  S. Ferrari,et al.  Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  W. Winkelmann,et al.  Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. , 1999, Medical and pediatric oncology.

[44]  A. Nakagawara,et al.  1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment. , 1999, Genes, chromosomes & cancer.

[45]  O. Myklebost,et al.  Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. , 1997, British Journal of Cancer.

[46]  H. Kovar,et al.  Regression and progression in neuroblastoma. Does genetics predict tumour behaviour? , 1995, European journal of cancer.

[47]  M. Valentine,et al.  A second nonrandom translocation, der(16)t(1;16)(q21;q13), in Ewing sarcoma and peripheral neuroectodermal tumor. , 1990, Cytogenetics and cell genetics.

[48]  W. Winkelmann,et al.  Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6‐year experience of a European cooperative trial , 1988, Cancer.

[49]  Chromosomal translocations in Ewing's sarcoma. , 1983, The New England journal of medicine.

[50]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[51]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[52]  D. Cox.  Regression Models and Life-Tables , 1972 .